{"id":"W3192736776","doi":"10.1136/jitc-2021-002863","title":"First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Novartis","keywords":"Medicine; Tolerability; Adverse effect; Pharmacokinetics; Pharmacodynamics; Internal medicine; Pharmacology; Toxicity; Oncology; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001995424,0.001885897,0.002492721,0.0004961272,0.0004550625,0.001037501,0.0009648142,0.0009472395,0.003068635],"category_scores_gemma":[0.0008765741,0.0008244221,0.0013837,0.0005539392,0.001376287,0.001087816,0.0005418326,0.003548779,0.0009207952],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001223309,"about_ca_system_score_gemma":0.001817738,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007331039,"about_ca_topic_score_gemma":0.001834643,"domain_scores_codex":[0.9993128,0.0003085929,0.00003446452,0.0001213661,0.00007850826,0.0001443569],"domain_scores_gemma":[0.9991642,0.0001023358,0.000167195,0.00009150134,0.00004849321,0.0004262528],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6663568,0.1461506,0.008043574,0.001133499,0.001550642,0.00033686,0.0005654368,0.003394045,0.0748558,0.0002346027,0.00372839,0.09364971],"study_design_scores_gemma":[0.4061886,0.5728328,0.01021121,0.00002991585,0.0004329237,0.0003354747,0.0000637287,0.0009179161,0.005898561,0.0001799452,0.002873254,0.00003563898],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9921468,0.002262433,0.0008823951,0.0002141435,0.00007593795,0.002363647,0.0009621072,0.00009043251,0.001002137],"genre_scores_gemma":[0.9891961,0.001511825,0.002354441,0.0005496232,0.0001612735,0.002559006,0.001933759,0.00004445476,0.001689576],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003068635,"threshold_uncertainty_score":0.01055294,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0333281760727157,"score_gpt":0.383287857769983,"score_spread":0.3499596816972673,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}